IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v9y2018i1d10.1038_s41467-018-03210-2.html
   My bibliography  Save this article

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Author

Listed:
  • Xiujuan Wu

    (Third Military Medical University)

  • Peng Tang

    (Third Military Medical University)

  • Shifei Li

    (Third Military Medical University)

  • Shushu Wang

    (Third Military Medical University)

  • Yueyang Liang

    (Third Military Medical University)

  • Ling Zhong

    (Third Military Medical University)

  • Lin Ren

    (Third Military Medical University)

  • Ting Zhang

    (Third Military Medical University)

  • Yi Zhang

    (Third Military Medical University)

Abstract

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3–4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.

Suggested Citation

  • Xiujuan Wu & Peng Tang & Shifei Li & Shushu Wang & Yueyang Liang & Ling Zhong & Lin Ren & Ting Zhang & Yi Zhang, 2018. "A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer," Nature Communications, Nature, vol. 9(1), pages 1-8, December.
    • Handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03210-2
    DOI: 10.1038/s41467-018-03210-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-018-03210-2
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-018-03210-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Yuanlin Wang & Yaqian Han & Chenhui Yang & Tiancheng Bai & Chenggang Zhang & Zhaotong Wang & Ye Sun & Ying Hu & Flemming Besenbacher & Chunying Chen & Miao Yu, 2024. "Long-term relapse-free survival enabled by integrating targeted antibacteria in antitumor treatment," Nature Communications, Nature, vol. 15(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03210-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.